Middle East & Africa Injectable Drug Delivery Market

As of 2025, formulations held the largest market share in the injectable drug delivery market in the Middle East & Africa, driven by the increasing number of biologics, vaccines, biosimilars, and chronic therapeutic injectables. Most countries in the region widely use ready-to-use or repackaged formulations to meet the increasing demands of large public health initiatives. Formulations are the therapeutic component of the treatment, independent of the type of devices used.

In 2025, the market for ampoules was dominant, as they are cheap, easy to manufacture, and can be used with various drugs such as vaccines or emergency products. Their high sterility assurance levels make them the preferred packaging solution for public health initiatives on a large scale by governments. Moreover, various health institutions in the region, especially those in emerging markets, still employ the classic vaccine delivery method using ampules, which are cheaper than other packaging solutions.

As of 2025, autoimmune diseases held the largest share in the market, which is driven by the increasing incidence of rheumatoid arthritis, multiple sclerosis, and other inflammation-related disorders in the region. These need to be treated with frequent biologics or targeted injectables. These products are primarily delivered through injectable drug delivery due to their complex molecular structure, which requires accurate dosing. Rising awareness levels and diagnosed cases, along with better access to specialty care, especially in the GCC countries, are other factors of growth.

As of 2025, the curative care segment accounted for the largest market share, as injectable drugs are predominantly used for the treatment of acute conditions, infectious diseases, and chronic ailments that require speedy treatment. Hospitals in the region are significantly dependent on injectable medications for their prompt therapeutic effects, which makes them a crucial aspect of emergency services, as well as inpatient facilities, and a key component of various disease control programs. A high prevalence of infectious as well as chronic diseases, including the enormous Government focus on treatment-based healthcare delivery, cements the position of the curative care segment in total injectable sales.

As of 2025, dermal-based administration had the largest market share, given that intradermal delivery is commonly used for vaccine delivery, immunotherapy, or other dose-sparing efforts crucial for public health campaigns in the region. This is an effective delivery mechanism that can generate robust immune reactions for a small volume of the vaccine, making it resource-efficient for mass vaccine delivery. Notably, the increasing adoption of microneedle/intradermal delivery systems is also beneficial for the growth of dermal-based delivery.

Hospitals and clinics accounted for the largest share among end-use segments, as they are key centers for the care of acute and chronic diseases that require injectable drugs. Most biologics, vaccinations, and special injectables are often given in hospitals or other medical facilities because they require monitoring by specialists. Furthermore, treatment provided in hospitals is more widely adopted compared to that in homes in some countries in the Middle East & Africa, implying that hospitals and clinics continue to be key end users.